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1. Introduction 
Diverse analogues of -amino nitrile-derived ureas have been 
described as inhibitors of the cholesteryl ester transfer protein
1
 
and diverse enzymes, such as dipeptidyl peptidase IV,
2-4
 prolyl 
oligopeptidases,
5
 and cysteine cathepsins,
6,7
 as well as agents for 
neurological disorders,
8
 pesticides,
9
 and fungicides.
10
 On the 
other hand, -amino nitrile-derived ureas are intermediates in the 
synthesis of diverse pharmacologically active hydantoin 
derivatives from -amino nitriles.
11-13
 In view of these precedents 
and in the context of a medicinal chemistry project focused on 
the search of antagonists of the thrombin receptor PAR1,
14,15
 by 
exploring the use of -amino acid-derived amino nitriles as 
molecular diversity generators,
16
 we have recently described a 
versatile solvent-free synthesis of basic amino acid-derived N-
(cyanomethyl)ureas of general formula A.
17
 Now, taking into 
account that hydantoins (imidazolidine-2,4-diones) are included 
among privileged scaffolds in medicinal chemistry,
18,19
 natural 
products
20-26
 and organic synthesis,
19,27
 we have studied and 
report herein the cyclization of cyanomethylureas  A to 
imidazolidin-2-one derivatives B (Scheme 1). 
 
 
 
 
 
 
 
Scheme 1. Proposed synthesis of imidazolidin-2-one 
derivatives B 
 
 
2. Results and discussion 
In general, the synthesis of hydantoins by cyclization of -
amino nitriles involves reaction with isocyanates, followed by in 
situ acid hydrolysis of the corresponding intermediate N-
(cyanomethyl)ureas.
28,29,11,30
 As we were interested in preserving 
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the Boc protection at the basic side chain of N-
(cyanomethyl)ureas A, the cyclization in acid media was initially 
excluded and we decided to try it first under neutral or basic 
reaction conditions. The ornithine derived N-(cyanomethyl)urea 
(S)-1a (Scheme 2) was chosen for setting up the methodology. 
The cyclization was initially attempted by heating (S)-1a in 
refluxing MeOH. As shown in Table 1 (entry 1), after 15 min  of 
reaction, the HPLC-MS analysis of the crude reaction mixture 
showed the presence of the epimeric mixture of 4-
iminoimidazolidin-2-ones (RS)-2a, as minor products (9%), 
along with oxidation products,
31,32
 the 5-hydroxy-4-
iminoimidazolidin-2-ones (RS)-3a (78%) and the 5-benzylidene-
4-iminoimidazolidin-2-one 4a (13%). To avoid oxidation, the 
next experiments were carried out under argon and MeOH was 
replaced by other solvents. In this way, the starting urea (S)-1a 
remained unaltered after 2 days in toluene or CH3CN at 100 ºC. 
Then, we tried to add a catalytic amount of base
33
 (10 %, Et3N, 
K2CO3, and Cs2CO3), which activated the reaction and decreased 
the formation of oxidation products. Thus, both Et3N in toluene 
and K2CO3, or Cs2CO3 in CH3CN led to ≈ 40% of (RS)-2a 
(entries 2-4). The increase of base to 100% and the reaction 
temperature up to 100 ºC, by MW irradiation, in CH3CN allowed 
to decrease the reaction time and to increase the yield of the 4-
iminoimidazolidin-2-ones (RS)-2a up to 88% (entry 5). Finally, 
the improvement was particularly noteworthy when the reaction 
was carried out without solvent (entries 6 and 7), which yielded 
quantitatively the desired products (RS)-2a after 5 min of 
reaction. 
 
 
 
Scheme 2. Cyclization of the N-(cyanomethyl)urea (S)-1a as indicated in Table 1 
 
 
 
 
Table 1  
Influence of reaction conditions on the synthesis of the 4-
iminoimidazolidin-2-ones (RS)-2a from (S)-1a 
     Yield (%)a 
Entry Base (%) Solvent T (ºC) t (min) (RS)-2a (RS)-3a 4a 
1 -- MeOH 75 15 9 78 13 
2 Et3N (10) Toluene 100 30 44 30 -- 
3 K2CO3 (10) CH3CN 80 30 43 25 -- 
4 Cs2CO3 (10) CH3CN 80 30 41 29 -- 
5b Et3N (100) CH3CN 100 15 88 12 -- 
6b Et3N (100) -- 100 5 99 -- -- 
7b K2CO3 (100) -- 100 5 99 -- -- 
a
Determined by HPLC-MS. 
b
MW irradiation. 
 
 
The HPLC-MS analysis of the solvent-free synthesis of (RS)-
2a (Table 1, entries 6 and 7) showed two peaks, at a lower 
retention time (3.52 and 3.59 min) that the starting N-
(cyanomethyl)urea (S)-1a  (4.59 min), both with identical [M+1]
+
 
mass to that of this urea. The 
1
H NMR spectrum of (RS)-2a in 
CDCl3 and in (CD3)2CO showed the presence of two isomers, as 
well as the disappearance of the ureido NH and the appearance of 
two signals for the 5-H of the imidazolidin-2-one ring at ≈ 0.45 
ppm higher field than the proton in position  to the CN group of 
(S)-1a. The imine NH proton could not be observed, probably 
due to its fast exchange. No significant changes were observed in 
the signals corresponding to the benzylamide group, with respect 
to those of the starting urea (S)-1a. This fact discarded the 
alternative cyclization through this group to give an isomeric 6-
imino-piperazine-2-one ring. The duplicity of peaks in the 
HPLC-MS and of signals in the NMR spectra indicated that the 
cyclization occurred with epimerization at the C5 due to an 
equilibrium between the 4-iminoimidazolidin-2-one structure 2a 
and its tautomer 4-amino-2,3-dihydro-1H-imidazol-2-one 5a 
(Scheme 3). The racemization of optically active 5-
benzylhydantoins has been explained through a similar 
tautomerism
34
 and Bepary et al. have recently reported the 
tautomerism of 2-iminoimidazolidin-2-ones.
35
  Interestingly, the 
HPLC-MS analysis of the cyclization of (S)-1a in MeOH (Table 
1, entry 1) showed only one peak at 3.67 min. This fact suggested 
us that the tautomer equilibrium could be controlled by the 
solvent and that 5a could be the main tautomer in MeOH. Then, 
we attempted to study this tautomer equilibrium by registering 
the 
1
H NMR spectrum of (RS)-1a in CD3OD at different times. 
After 3 h, the cyclization was complete, but, unfortunately, the 
overlapping of the CD3OD signals with those of the cyclization 
products avoided their unequivocal assignment. We also tried to 
trap the tautomers by acetylation. For that purpose, the 
cyclization of (S)-1a was carried out solvent-free and under Ar, 
by MW heating at 100 ºC in the presence of 2 equivalents of 
acetyl chloride and Et3N. The HPLC-MS analysis of the crude 
reaction mixture showed the formation of a unique acetylated 
derivative, to which we assigned the structure of the 4-
acetamido-2,3-dihydro-1H-imidazol-2-one 6a, based on its 
1
H 
NMR spectrum in CDCl3. Thus, the 5-H proton of (RS)-2a had 
disappeared and the 5-CH2 protons appeared as an AB system [at 
3.72 and 3.79 ppm and J = 16.5 Hz, ≈ 0.5 ppm lower field than 
the corresponding protons in (RS)-2a]. However, the acetylated 
compound 6a resulted highly unstable and the NMR sample 
completely decomposed during the 
13
C NMR registration time (≈ 
8 h). This 
13
C NMR spectrum showed a complex mixture that 
could not be assigned. The decomposition was also evident in the 
HPLC-MS analysis of the recovered NMR sample, which 
showed the almost complete disappearance of the peak 
corresponding to 6a and the appearance of multiple peaks of 
oxidation products. 
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Scheme 3. Synthesis, tautomerism and acetylation of the 4-iminoimidazolidin-2-ones (RS)-2a 
 
 
In view of the epimerization observed in the cyclization of 
(S)-1a, the versatility of the MW-promoted and base-catalyzed 
solvent-free cyclization was studied using epimeric mixtures of 
the N-(cyanomethyl)ureas (RS)-1a-e (Scheme 4). In this way, the 
corresponding 4-iminoimidazolidin-2-ones (RS)-2a-e were 
obtained in higher than 95 % yield. Although the HPLC analysis 
of the crude reactions showed a high degree of purity, the NMR 
spectra of (RS)-2a-e showed low resolution, due to the presence 
of mixtures of epimers and to the high tendency of these 4-
iminoimidazolidin-2-ones to oxidation. The assignment of these 
spectra was based on 2D HSQC and HMBC spectra. 
 
 
Starting urea  Iminoimidazolidin-2-one 
no. m n R1  no. yield 
(RS)-1a 1 3 Ph  (RS)-2a 97 
(RS)-1b 1 3 Bn  (RS)-2b 95 
(RS)-1c 1 3 4-MeO-Ph-(CH2)2  (RS)-2c 95 
(RS)-1d 1 3 4-F-Ph-(CH2)2  (RS)-2d 96 
(RS)-1e 2 4 Ph  (RS)-2e 95 
 
Scheme 4. Synthesis of the 4-iminoimidazolidin-2-ones (RS)-
2a-e 
 
4-Iminoimidazolidin-2-ones are known to give hydantoins in 
acid media.
34,28,36
 Based on this knowledge, we decided to study 
the hydrolysis of (RS)-2a-e to the corresponding hydantoin 
derivatives. We first tried the hydrolysis in acid conditions 
compatible with the presence of the Boc protection in the basic 
side chain, such as (0.1-1.0 N) HCl in EtOAc, 20% AcOH in 
MeOH or (1:1:1) AcOH/MeOH/H2O at rt. In all cases, the 
starting 4-iminoimidazolidin-2-ones (RS)-2a were recovered 
unaltered. Then, we tried the standard acid conditions for Boc 
removal, 3N HCl in EtOAc and 20% TFA in CH2Cl2, at rt. After 
30 min, the removal of the Boc group was complete in both 
cases, but the iminoimidazolidin-2-one ring was unaltered. After 
24 h, the HPLC-MS of the crude reaction mixture showed 58 % 
of ring oxidation, but no hydrolysis. Finally, we studied the 
hydrolysis of (RS)-2a at 100 ºC in concentrated aqueous HCl (12 
N). Under these conditions, complete hydrolysis required 
overnight heating, which, besides the hydrolysis of the 
iminoimidazolidin-2-one ring, also produced the hydrolysis of 
the benzyl amide group at the basic amino acid residue to 
carboxylic acid and partial oxidation of the ring (Scheme 5). The 
mixture of products (RS)-9a and 10a, although was identified by 
their [M+1]
+
 in the HPLC-MS analysis, could not be separated. 
 
 
Scheme 5. Acid hydrolysis of the 4-iminoimidazolidin-2-ones 
(RS)-2a 
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In view of the difficulties to obtain hydantoins by hydrolysis 
of 4-iminoimidazolidin-2-ones, we turned to study their 
preparation by direct hydrolysis of the starting N-
(cyanomethyl)ureas (S)-1a-e. The setting up of reaction 
conditions was carried out with (S)-1a. As shown in Table 2, 
treatment of this urea with 0.1 N solution of HCl in EtOAc for 3 
days led almost quantitatively to the Boc-protected 4-
iminoimidazolidin-2-ones (RS)-2a (entry 1), while, increasing 
the HCl concentration up to 3 N gave a mixture of deprotected 
iminoimidazolidin-2-ones (RS)-7a and the hydantoin (S)-12a 
(entry 3). As shown in Scheme 6, this compound was the only 
reaction product when the hydrolysis was carried out in 20 % 
TFA solution in CH2Cl2 at rt (entry 4) or in 12 N aqueous HCl at 
100 ºC (entry 5). In this latter case, neither hydrolysis of the 
benzyl amide group nor epimerization at C5 was observed. This 
different behavior respect to the commented hydrolysis of 4-
iminoimidazolidin-2-ones (RS)-2a suggested that the hydrolysis 
mechanism was different and that it should not go through the 4-
iminoimidazolidin-2-ones (RS)-7a. To study the process, the 
TFA-mediated reaction was monitored by HPLC-MS at different 
times. After 5 h, the starting urea (tR = 5.79 min, [M+1]
+
 = 
570.46) was completely transformed into the acid (S)-11a (tR = 
3.25 min, [M+1]
+
 = 488.46), that, after 24 h, completely cyclized 
to the hydantoin (S)-12a (tR = 3.30 min, [M+1]
+
 = 471.99). This 
two-step hydrolysis was also monitored by 
1
H NMR in CDCl3, 
which confirmed the mechanism. In view of the good results of 
this methodology, it was applied to the synthesis of the series (S)-
12a-e (Scheme 6). These hydantoins derivatives were isolated 
from the reaction mixtures as TFA salts in higher than 95 % yield 
and were screened as antagonists of the thrombin receptor PAR1 
in an assay of human platelet aggregation inhibition.
14
 None of 
them displayed significant activity at 0.1 mg/mL concentration. 
 
Table 2  
Influence of the acid media in the hydrolysis of the N-
(cyanomethyl)urea (S)-1a 
    Yield (%)a 
Entry Acid T (ºC) t (RS)-2a (RS)-7a (S)-12a 
1 0.1 N HCl/EtOAc rt 3 days 95 - - 
2 0.3 N HCl/EtOAc rt 15 min 62 38 - 
3 3 N HCl/EtOAc rt 30 min - 55 45 
4 20% TFA/CH2Cl2 rt 24 h - - 95
b 
5 12 N HCl/H2O 100 30 min - - 85
b 
a
Determined by HPLC-MS analysis of the crude reaction. 
Sunfire C18 (4.6×50 mm, 3.5 m). 
b
Isolated  yield. 
 
 
 
Scheme 6. Synthesis of the hydantoin derivatives (S)-12a-e by acid hydrolysis of the N-(cyanomethyl)ureas (S)-1a-e 
 
 
3. Conclusions 
In conclusion, the results herein described show that N-
(cyanomethyl)ureas display a chameleonic reactivity that can act 
as a double-edged sword. Adequately controlled, this reactivity 
may have high synthetic potentiality. Thus, under neutral, basic 
or mild acid media they cyclize to 4-iminoimidazolidin-2-one 
derivatives, which tautomerize to 4-amino-2,3-dihydro-1H-
imidazol-2-ones. This tautomerism triggers epimerization at the 
C5 of the imidazolidine ring, as well as its oxidation. However, 
under strong acid media, N-(cyanomethyl)ureas in a no-
epimerizing two-step hydrolysis, through the corresponding 
carboxylic acids, give stable highly functionalized hydantoin 
derivatives. 
 
4. Experimental section 
4.1. General methods 
All reagents were of commercial quality. Solvents were dried 
and purified by standard methods. Analytical TLC was 
performed on aluminum sheets coated with a 0.2 mm layer of 
silica gel 60 F254. Silica gel 60 (230-400 mesh) was used for flash 
chromatography. Analytical RP-HPLC was performed on a 
Sunfire C18 (4.6×150 mm, 3.5 μm) column, with a flow rate of 1 
mL/min, using a tunable UV detector set at 214 and 254 nm and 
gradient of CH3CN (solvent A) and 0.05 % TFA in H2O (solvent 
B) as mobile phase. HPLC-MS was performed on a Sunfire C18 
(4.6×50 mm, 3.5 μm) column at 30°C, with a flow rate of 1 
mL/min and gradient of 0.1% of formic acid in CH3CN (solvent 
A) in 0.1% of formic acid in H2O (solvent B) was used as mobile 
phase. Electrospray in positive mode was used for ionization. 
NMR spectra were recorded using Varian Inova 300, Varian 
Inova or Mercury 400, and Varian Unity 500 spectrometers. The 
NMR spectra assignments were based on COSY, HSQC, and 
HMBC spectra. MW experiments were carried out in sealed 
vessels in a MW Emrys
TM
 Synthesizer (Biotage AB), with 
transversal IR sensor for reaction temperature monitoring. 
4.2. General procedure for the solvent-free synthesis of the 4-
iminoimidazolidin-2-ones (RS)-2a-e 
Et3N (28 L, 0.2 mmol) was added under argon to a solution 
of the corresponding N-(cyanomethyl)urea (RS)-1a-e (0.2 mmol) 
in CH2Cl2 (0.50 mL). After 5 min of stirring at room temperature, 
the solvent was evaporated under argon stream. The 
homogeneous mixture was heated at 100 ºC by MW irradiation 
for 5 min. After cooling to rt, the crude reaction was dissolved in 
EtOAc (10 mL), washed with H2O (3×3 mL) and brine (3 ml), 
dried over Na2SO4, and concentrated under vacuum. The residue 
was purified by flash chromatography, using 0-15% MeOH in 
 5 
CH2Cl2 gradient as eluent, to afford the title compounds (RS)-2a-
e as foams that decomposed on standing. 
4 .2 .1 .  te r t -Butyl  [ (4S )-4 - (5-benzyl -4- imino -2 -oxo -3-
phenyl imidazol id in -1-yl )-5-(benzy lamino) -5-
oxopenty l] carbamate  (RS ) -2a .Yield  97  %; foam;  
HPLC-MS (15-95 % grad ient  of  A in  B for  5  min )  tR  
3 .55  and  3 .61  min ;  
1
H NMR [ (CD 3 ) 2CO,  300 MHz]    
1 .26  (s ,  9H,  Boc) ,  1.43  (m,  2H) ,1 .96  (m,  2H),  2 .91-
3 .35  (m,  4H),  4 .15 -4 .42  (2m,  3H),  4 .50  ( t ,  J=5 Hz,  
0 .5H),  4 .68  ( t ,  J=5 Hz,  0 .5H),  5 .96  (b r  s ,  1H),  6 .79 -
7 .43  (m,  15H),  7 .87  and 7 .91  (2 t ,  J=6 Hz,  1H) ;  
1 3
C 
NMR [(CD 3 ) 2CO, 100  MHz]    27 .2 ,  27 .8 ,  28 .0 ,  28 .4  
(CH 2 ) ,  28 .7  (CH 3 ) ,  38 .3 ,  38 .8 ,  40 .4 ,  40 .5 ,  43 .5 ,  43 .7  
(CH 2 ) ,  57 .7 ,  59 .4 ,  60 .0 ,  61 .9  (CH),  78 .5  (C),  127 .7 ,  
127.8 ,  127.8 ,  128.3 ,  128.5 ,  129.0 ,  129.1 ,  129.2 ,  
129.4 ,  131.0  131.1  (CH),  136.6 ,  140.0 ,  140.1 ,  141.2  
(C),  156.8 ,  157.8 ,  170.8,  171.0  (CO).  ES-MS m/z  
[M+1]
+
 calcd  fo r  C 3 3H 3 9N 5O 4  570.3 ,  found,  570.4 .  
4 .2 .2 .  te r t -Butyl  [ (4S )-5 - (benzylamino)-4 - (3 ,5 -
dibenzy l -4 -imino -2-oxoimidazol id in -1-yl ) -5-
oxopenty l] carbamate  (RS ) -2b .Yield  95  %; foam;  
HPLC-MS (15-95 % grad ient  of  A in  B for  5  min )  tR  
3 .67  and  3 .77  min ;  
1
H NMR [ (CD 3 ) 2CO,  400 MHz]    
1 .25  (s ,  9H,  Boc) ,  1.38 (m,  2H) ,1 .93  (m,  2H),  2 .83-
3 .25  (m,  4H) ,  4 .12-4 .60  (m,  6H),  5 .92  (br  s ,  1H),  
6 .93-7 .22  (m,  15H),  7 .74  and 7 .86  (2 t ,  J=6 Hz,  1H) ;  
1 3
C NMR [(CD 3 ) 2 CO, 100 MHz]    27 .0 ,  27 .8 ,  27 .9 ,  
28 .4  (CH 2 ) ,  28 .6  (CH 3 ) ,  37 .8 ,  38 .1 ,  40 .3 ,  40 .5 ,  42 .6 ,  
43 .5 ,  43 .7 ,  44 .4  (CH 2 ) ,  57 .8 ,  59 .1 ,  59 .7 ,  62 .0  (CH),  
78 .5  (C),  127.6 ,  127.7 ,  127.8 ,  128.2 ,  128.2 ,  128 .4 ,  
129.0 ,  129.0 ,  129.1 ,  129.2 ,  130.8 ,  130.9  (CH),  
136.4 ,  140.0 ,  140.0  (C),  156.8 ,  158.9 ,  159.1 ,  171.0  
(CO).  ES-MS m/z  [M+1] +  ca lcd  for  C 3 4 H 4 1 N 5 O 4  
584.3 ,  found,  584.4 .  
4 .2 .3 .  te r t -Butyl  [ (4S ) -4- (5 -benzyl -4 -imino-3 - (4-
methoxyphenethyl ) -2 -oxo imidazol id in -1-yl )-5 -
(benzylamino) -5 -oxopen tyl] carbamate  carbamate  
(RS ) -2c .Yield  95  %; foam; HPLC-MS (15-95 % 
gradient  of  A in  B fo r  5  min )  t R  3 .61  min;  
1
H NMR 
[(CD 3 ) 2 CO, 300 MHz]    1 .25  (s ,  9H,  Boc),  1.33 (m,  
2H),1 .95  (m,  2H),  2 .45 ,  2 .70 ,  2 .98 ,  3 .24 ,  3 .41  (5m,  
8H),  3 .61  and 3 .62  (2s ,  3H),  4 .05-4 .48  (m,  6H),  
5 .92  (br  s ,  1H),  6 .70  (d ,  J=9 Hz,  2H),  6 .93  (dd ,  J=9,  
3  Hz,  2H) ,  7 .00-9 .19  (m,  12H),  7 .68  and 7 .82  (2 t ,  
J=6 Hz,  1H) ;  
1 3
C NMR [ (CD 3 ) 2CO, 75  MHz]    26 .5 ,  
27 .0 ,  28 .0 ,  28 .7  (CH 2 ) ,  28 .9  (CH 3 ) ,  33 .1 ,  33 .3 ,  38 .6 ,  
38 .9 ,  40 .7 ,  40 .9 ,  43 .8 ,  44 .0 ,  44 .1 ,  44 .2  (CH 2 ) ,  55 .7  
(CH 3 ) ,  56 .9 ,  57 .9 ,  60 .0 ,  62 .2  (CH),  78 .8  (C),  114 .9 ,  
127.7 ,  127.9 ,  127.9 ,  128.5 ,  128.6 ,  128.9 ,  129.2 ,  
129.3 ,  129.3 ,  129.5 ,  130.7 ,  130.7 ,  130.8 ,  130.9 ,  
131.7  (CH),  136.8 ,  137.0 ,  140.3  (C),  157.0 ,  158 .7 ,  
159.5 ,  159.5 ,  171.2 ,  171.3  (CO) .  ES-MS m/z  [M+1] +  
calcd  for  C 3 6 H 4 5 N 5 O 5  628 .3 ,  found,  628.5 .   
4 .2 .4 .  te r t -Butyl  [ (4S ) -4- (5 -benzyl -3- (4 -
f luorophene thyl ) -4- imino-2-oxoimidazol id in -1 -y l) -
5-(benzy lamino) -5-oxopentyl] carbamate  (RS ) -
2d .Yie ld  96  %; foam; HPLC-MS (15-95 % gradient  
of  A in  B for  5  min )  t R  3 .67  and 3 .72  min;  
1
H NMR 
[(CD 3 ) 2 CO, 500 MHz]    1 .26  (s ,  9H,  Boc),  1.36 (m,  
2H),1 .92  (m,  2H),  2 .35 -3 .58  (m,  8H),  4 .09  ( t ,  J=7 
Hz,  0 .5H) ,  4 .24  and 4 .34  (2m,  2 .5H),  4 .48  (b r  s ,  
0 .5H),  4 .61  (b r  s ,  0 .5H),  5 .91  (b r  s ,  1H) ,  6 .87  (dd ,  
J=9 ,  3  Hz,  1H),  6 .89  (dd ,  J=9,  3  Hz,  1H),  6 .97–7.27 
(m,  10H),  7 .76  and 7 .82  (2 t ,  J=6 Hz,  1H;  
1 3
C NMR 
[(CD 3 ) 2 CO, 125 MHz]    25 .8 ,  26 .4 ,  26 .5 ,  26 .8  
(CH 2 ) ,  27 .2  (CH 3 ) ,  31 .4 ,  31 .7 ,  36 .4 ,  36 .9 ,  38 .9 ,  
39 .1 ,  39 .2 ,  39 .4 ,  42 .2 ,  42 .4  (CH 2 ) ,  56 .7 ,  58 .1 ,  58 .3 ,  
60 .4  (CH),  77 .1 ,  77 .5  (C) ,  114.3 ,  114.5 ,  126.4 ,  
126.5 ,  126.5 ,  126.8 ,  126.9 ,  126.9 ,  127.1 ,  127.4 ,  
127.5 ,  127.7 ,  127.8 ,  127.8 ,  127.8 ,  127.8 ,  127.8 ,  
127.9 ,  129.5 ,  129.6 ,  130.1 ,  130.1 ,  130.2  (CH),  
133.8 ,  134.9 ,  138.5 ,  138.7  (C),  155.5 ,  156.4 ,  160.1 ,  
162.0 ,  162.1 ,  169.3 ,  169.5  (CO) .  ES-MS m/z  [M+1] +  
calcd  for  C 3 5 H 4 2 FN 5 O 4  616.3 ,  found,  616.5 .  
4 .2 .5 .  ter t -Buty l  [ (5S ) -6- (benzylamino) -5- (4 -imino-
2-oxo -5-phenethyl -3-phenyl imidazol id in -1 -y l) -6 -
oxohexyl] carbamate  (RS ) -2e .Yield  95  %; foam;  
HPLC-MS (15-95 % grad ient  of  A in  B for  5  min )  tR  
3 .57  min;  
1
H NMR [ (CD 3 ) 2CO, 300 MHz]    1 .25  (s ,  
9H,  Boc),  1.29,  1 ,38   (2m,  4H),1 .79-2 .27  (m,  4H),  
2 .37-3 .01  (m,  6H),  4 .34  (m,  4H),  5 .84  (br  s ,  1H),  
7 .01-7 .49  (m,  15H),  7 .70  and 7 .98  (2 t ,  J=6 Hz,  1H) ;  
1 3
C NMR [(CD 3 ) 2CO, 75  MHz]    23 .2 ,  27 .2  (CH 2 ) ,  
27 .4  (CH 3 ) ,  29 .6 ,  33 .0 ,  33 .5 ,  34 .4 ,  34 .6 ,  39 .6 ,  42 .4 ,  
42 .6  (CH 2 ) ,  56 .3 ,  57 .2 ,  58 .9 ,  59 .6  (CH),  77 .1  (C),  
125.3 ,  125.4 ,  126.4 ,  127.0 ,  127.1 ,  127.8 ,  127.8 ,  
127.8 ,  127.9 ,  127.9 ,  128.0 ,  128.1  (CH),  138.8 ,  
138.9 ,  139.9 ,  140.1 ,  141.0 ,  141.1  (C),  155.3 ,  155.7 ,  
156.5 ,  169.5 ,  169.7  (CO) .  ES-MS m/z  [M+1] +  calcd 
for  C 3 5 H 4 3 N 5 O 4  598.3 ,  found,  598.3 .  
4.3. Cyclization-acetylation of the N-(cyanomethyl)urea (S)-
1a. Synthesis of (S)-tert-butyl (4-(4-acetamido-5-benzyl-2-oxo-
3-phenyl-2,3-dihydro-1H-imidazol-1-yl)-5-(benzylamino)-5-
oxopentyl)carbamate 6a. 
Et3N (8.4 L, 0.06 mmol) and acetyl chloride (4.3 L, 0.06 
mmol) were added under argon to a solution of the N-
(cyanomethyl)urea (S)-1a (17.2 mg, 0.03 mmol) in CH2Cl2 (0.50 
mL). After 5 min of stirring at room temperature, the solvent was 
evaporated under argon stream. The homogeneous mixture was 
heated at 100 ºC by MW irradiation for 25 min. After cooling to 
rt, the crude reaction mixture was purified by flash 
chromatography, using 0-5% MeOH in CH2Cl2 gradient as 
eluent, to afford the title compounds 6a (11 mg, 60%) as a foam 
that decomposed on standing. HPLC-MS: tR 5.61 min. 
1
H NMR 
(CD3Cl, 300 MHz)  1.06 (m, 2H), 1.34 (s, 9H), 1.80 (s, 3H), 
2.00 (m, 2H), 2.80 (m, 2H), 3.70 and 3.82 (2d, J = 16.5 Hz, 2H), 
4.43-4.15 (m, 4H), 6.51 (s, 1H), 7.45-7.05 (m, 15H), 7.99 (s, 1H). 
The instability of this compound did not allow obtaining its 
13
C 
NMR spectrum. ES-MS m/z [M+1]
+
 calcd for C35H41N505 612.31, 
found, 612.31. 
4.4. Acid hydrolysis of the N-(cyanomethyl)ureas (S)-1a-e. 
Synthesis of the hydantoin derivatives (S)-12a-e. 
The corresponding N-(cyanomethyl)urea (S)-1a-e [0.125 
mmol, impurified with 0-30 % of the respective epimer (R)-1a-e, 
due to the difficulty of resolution of the epimeric mixtures (RS)-
1a-e] was dissolved in 20 % solution of TFA in CH2Cl2 (5 mL). 
After 24 h of stirring at rt, the reaction mixture was evaporated to 
dryness. The residue was coevaporated with CH2Cl2 (3×2 mL) 
and triturated with cold ethyl ether. The residue was dissolved in 
H2O (3 mL) and the solution was lyophilized. In this way, the 
trifluoroacetates of the hydantoin derivatives (S)-12a-e were 
obtained as amorphous solids retaining the epimer ratio of the 
starting urea 1a-e [70-100 % of the (S)-epimer]. 
4 .4 .1 .  (2S )-5 -Amino-N -benzy l -2 -[ (S )-5 -benzyl -2 ,4 -
dioxo-3 -phenyl imidazol id in -1 -yl] pentanamide 
tr i f luoroace ta te  (S ) -12a .   With  ≈28% of  the  epimer  
(R )-12a ,  yield  96  %; foam; HPLC-MS (15-95 % 
gradient  of  A in  B fo r  5  min )  t R  3 .08  min ;  
1
H NMR 
[CD 3OD, 500 MHz]    1 .60  (m,  2H),2 .05  (m,  2H),  
2 .86  (m,  2H),  3 .18  (dd ,  J=5,  15 .5  Hz,  1H) ,  3 .25  (dd ,  
J=5,  15 .5  Hz,  1H),  4 .16  ( t ,  J=8 Hz,  1H) ,  4 .27  and 
4 .35  (AB s ystem,  J=15 Hz,  2H),  4 .45  ( t ,  J=8 Hz,  
0 .28H),  4 .55  ( t ,  J=5H,  0 .78H),   6 .72 -7 .41  (m,  15H),  
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8.26  and 8 .45  (2 t ,  J=6 Hz ,  1H);  
1 3
C NMR [CD 3 OD,  
125  MHz]    24 .2 ,  26 .8 ,  36 .1 ,  38 .7 ,  38 .7 ,  42 .9 ,  43 .0  
(CH 2 ) ,  57 .9 ,  58 .0 ,  59 .2 ,  60 .9 ,  61 .6  (CH),  126.2 ,  
127.0 ,  127.0 ,  127.3 ,  128.1 ,  128.1 ,  128.2 ,  128.2 ,  
128.5 ,  128.6 ,  129.3 ,  131.3  (CH),  134.7 ,  137.0 ,  
138.1  (C),  156.3 ,  169.7 ,  169.7 ,  171.4 ,  172.3  (CO).  
ES-MS m/z  [M+1]
+
 calcd  for  C 2 8 H 3 0N 4 O 3  471.2 ,  
found,  471.4 ;  Anal  calcd  for  C 2 8H 3 0 N 4O 3 ·C 2H F3 O:  
C,  61 .64;  H,  5 .35;  N,  9 .58 .  Found:  C,  61 .38;  H,  
5 .46;  N,  9 .37 .  
4 .4 .2 .  (2S )-5 -Amino-N -benzy l -2 -[ (S )-3 ,5 -dibenzyl -
2 ,4-dioxo imidazo l id in -1-yl] pentanamide 
tr i f luoroace ta te  (S ) -12b .   With  ≈25% of  the  epimer  
(R )-12b ,  yield  95  %;  foam; HPLC -MS (15-95  % 
gradient  of  A in  B fo r  5  min )  t R  3 .22  min;  
1
H NMR 
[CD 3OD, 500 MHz]    1 .54  and 1 .71  (2m,  2H),1 .90 ,  
2 .03 ,  2 .14  (3m,  2H),  2 .82  ( t ,  J=7 Hz ,  2H),  3 .14  (m,  
2H),  4 .09  ( t ,  J=8 Hz ,  0 .75H),  4 .17 -4 .50  (m,  5 .25H),  
6 .83-7 .35  (m,  15H) ;  
1 3
C NMR [CD 3 OD, 125 MHz]    
25 .6 ,  28 .2 ,  36 .6 ,  40 .1 ,  43 .2 ,  44 .3  (CH 2 ) ,  59 .3 ,  63 .2  
(CH),  128.3 ,  128.4 ,  128.4 ,  128.7 ,  128.7 ,  129.0 ,  
129.4 ,  129.5 ,  129.6 ,  129.6 ,  129.6 ,  129.9 ,  130.2 ,  
130.7 ,  131.1  (CH),  136.0 ,  137.0 ,  139.3  (C),  158 .7 ,  
159.9 ,  170.9 ,  171.2 ,  173.7 ,  174.3  (CO).  ES-MS m/z  
[M+1]
+
 calcd  fo r  C 2 9H 3 2 N 4O 3  485.3 ,  found,  485.5 ;  
Anal  ca lcd  for  C 2 9 H 3 2 N 4O 3 ·C 2 HF3 O: C,  62 .20;  H,  
5 .56;  N,  9 .36 .  Found:  C,  62 .03;  H,  5 .49;  N,  9 .06 .  
4 .4 .3 .  (2S )-5 -Amino-N -benzy l -2 -[ (S )-5 -benzyl -3 -(4 -
methoxyphenethyl ) -2 ,4 -dioxoimidazo l id in -1 -
yl] pentanamide tr i f luoroaceta te  (S )-12c .  With  
≈30% of  the ep imer (R )-12c ,  yie ld  97  %; foam;  
HPLC-MS (15-95 % grad ient  of  A in  B for  5  min )  tR  
3 .23  min ;  
1
H NMR [CD 3 OD, 500 MHz]    1 .52  and 
1 .68  (2m,  2H),1 .87 ,  1 .96 ,  2 .06  (3m,  2H),  2 .40  ( t ,  
J=8  Hz ,  0 .6H),  2 .49  (m,  1 .4H),  2 .81  ( t ,  J=7.5  Hz,  
1 .4H),  2 .94 -2 .09  (m,  2H) ,  3 .12  (m,  0 .6H) ,  3 .31-3 .51  
(m,  2H),  3 .63  and 3 .64  (2 s ,  3H),  3 .99  (m,  1 .4H),  
4 .16-4 .32  (m,  2 .6H),  6 .70  (m,  2H),  6 .91  (m,  2H),  
7 .02  (m,  2H),  7 .09  (m,  2H),7 .14 -7 .21  (m,  4H),  7 .34  
(m,  2H) ;  
1 3
C NMR [CD 3 OD, 125 MHz]    25 .6 ,  28 .2 ,  
33 .7 ,  37 .2 ,  40 .1 ,  41 .1 ,  44 .3  (CH 2 ) ,  55 .7  (CH 3 ) ,  59 .2 ,  
63 .2  (CH),  115.0 ,  115.0 ,  128.3 ,  128.4 ,  128.7 ,  129.4 ,  
129.6 ,  129.6 ,  129.9 ,  130.2 ,  130.7 ,  130.8 ,  130.8 ,  
131.0  (CH),  136.4 ,  139.5 ,  159.9  (C),  158.5  171.3 ,  
173.7  (CO).  ES-MS m/z  [M+1] +  calcd  for  
C 3 1H 3 6 N 4O 4  529.3 ,  found,  529.4 ;  Anal  calcd  for  
C 3 1H 3 6 N 4O 4 ·C 2H F3 O: C,  61 .67;  H,  5 .80;  N,  8 .72 .  
Found:  C,  61 .47;  H,  5 .89;  N,  8 .45 .  
4 .4 .4 .  (2S )-5 -Amino-N -benzy l -2 -[ (S )-5 -benzyl -3 -(4 -
f luorophene thyl ) -2 ,4-d ioxoimidazol id in -1 -
yl] pentanamide tr i f luoroaceta te  (S ) -12d .  With 
≈25% of  the epimer (R )-12d ,  yie ld  97  %; foam;  
HPLC-MS (15-95 % grad ient  of  A in  B for  5  min )  tR  
3 .31  min ;  
1
H NMR [CD 3 OD, 500 MHz]    1 .53  and 
1 .70  (2m,  2H),1 .87 ,  1 .98 ,  2 .08  (3m,  2H),  2 .44 -2 .59  
2 .49  (m,  2H),  2 .82  ( t ,  J=7.5  Hz,  1 .5H),  2 .96 -3 .10 
(m,  2H),  3 .13  (m,  0 .5H) ,  3 .35-3 .53  (m,  2H),  4 .02  
(m,  1 .4H),  4 .17-4 .34  (m,  2 .6H),  6 .87  (m,  2H),  7 .01  
(m,  3H),  7 .10  (m,  2H),  7 .19  (m,  5H),  7 .34  (m,  2H) ;  
1 3
C NMR [CD 3 OD,  125 MHz]    24 .1 ,  26 .8 ,  32 .3 ,  
35 .7 ,  38 .7 ,  39 .5 ,  42 .9  (CH 2 ) ,  57 .8 ,  61 .7  (CH),  
114.6 ,  114.8 ,  126.9 ,  127.0 ,  127.3 ,  127.9 ,  128.1 ,  
128.2 ,  128.5 ,  128.7 ,  129.3 ,  129.5 ,  130.1 ,  130.1  
(CH),  133.7 ,  134.9 ,  135.3 ,  138.0 ,  162.6  (C),  157.1 ,   
169.8 ,  172.2  (CO).  ES-MS m/z  [M+1] +  calcd  for  
C 3 0H 3 3 FN 4 O 3  517.3 ,  found,  517.4 ;  Anal  calcd  for  
C 3 0H 3 3 FN 4 O 3 ·C 2 HF3 O: C,  60 .95;  H,  5 .43 ;  N,  8 .88 .  
Found:  C,  60 .65;  H,  5 .27;  N,  8 .69 .  
4.4 .5 .  (S )-6 -Amino-N -benzy l -2 -[(S ) -2 ,4-d ioxo -5-
phenethy l -3 -phenyl imidazol id in -1 -yl] hexanamide 
tr i f luoroace ta te  (S ) -12e .   Yie ld  97  %; foam; HPLC-
MS (15-95 % gradient  of  A in  B for  5 min )  t R  3 .26  
min;  
1
H NMR [CD 3OD, 500 MHz]    1 .38  (m,  2H),  
1 .60  (m,  2H),  2 .00  (q ,  J=8 Hz,2H),  2 .12  and 2 .21  
(2m,  2H),  2 .51  and 2 .72  (2m,  2H),  2 .79  ( t ,  J=7 Hz,  
2H),  4 .26-4 .36  (m,  4H)) ,   7 .07-7 .38  (m,  15H; 
1 3
C 
NMR [CD 3 OD,  125 MHz]    24 .5 ,  28 .2 ,  30 .7 ,  31 .2 ,  
33 .3 ,  40 .4 ,  44 .3  (CH 2 ) ,  59 .3 ,  61 .8  (CH),  127.3 ,  
127.8 ,  127.8 ,  128.4 ,  128.7 ,  129.3 ,  129.4 ,  129.4 ,  
129.5 ,  129.6 ,  129.6 ,  129.6 ,  129.6 ,  130.0  (CH),  
133.1 ,  139.7 ,  141.8  (C),  157.7 ,  171.4 ,  173.4  (CO).  
ES-MS m/z  [M+1]
+
 calcd  for  C 3 0 H 3 4 N 4 O 3  499.3 ,  
found,  499.3 ;  Anal  calcd  for  C 3 0H 3 4 N 4O 3 ·C 2H F3 O:  
C,  62 .74;  H,  5 .76;  N,  9 .15 .  Found:  C,  62 .85;  H,  
5 .83;  N,  8 .89 .  
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